HealthcareUS health authority says Moderna vaccine effective in under-fives

US health authority says Moderna vaccine effective in under-fives


vaccine
Credit: Pixabay/CC0 Public Domain

US health authorities confirmed on Friday that data provided by drug-maker Moderna on the efficacy of its COVID-19 vaccine among very young children were accurate, ahead of a decision next week on whether to authorize two inoculations against the virus in kids aged six months to five years.

The Food and Drug Administration (FDA), which independently analyzed from conducted by Moderna, said against symptomatic cases of COVID-19 was 51 percent in babies aged six months to less than two years old, and 37 percent in children aged two to five years.

The figures are lower than those recorded during clinical trials on adults, but that is only because the trials for the very were conducted during a wave linked to the Omicron variant, according to the FDA.

“Although the VE (vaccine efficacy) … in children six months to five years is lower than that observed in the pivotal adult or older pediatric studies, it is highly consistent with real-world vaccine effectiveness observed against Omicron in adults,” the FDA said in a statement.

Even though Moderna’s vaccine has proven less effective against the Omicron variant, it remains very good at protecting against severe cases of the disease, the FDA pointed out.

That is why the FDA concluded that the Moderna data “support the administration” of the vaccine in two doses of 100 micrograms each in adolescents aged 12 to 17, 50 micrograms for six to 11 year olds, and 25 micrograms in children aged six months to five years.

In the United States, Moderna’s vaccine is currently only authorized for people aged 18 and older.

The latest document, stretching to more than 100 pages and published by the US agency, will serve as a basis for the authorization discussions next week.

An advisory committee of experts must meet over two days to study the request for authorization of the vaccine, as well as that of Pfizer, and make its recommendation.

The FDA is expected to publish its independent analysis of data from Pfizer early next week.

Pfizer has filed an application for authorization for children aged six months to four years, although its vaccine will be administered in three doses.


Pfizer asks FDA to OK COVID-19 vaccine for under 5s


© 2022 AFP

Citation:
US health authority says Moderna vaccine effective in under-fives (2022, June 10)
retrieved 10 June 2022
from https://medicalxpress.com/news/2022-06-health-authority-moderna-vaccine-effective.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.





Original Source Link

Latest News

Why the Fed keeping rates higher for longer may not be such a bad thing

US Federal Reserve Board Chairman Jerome Powell arrives to testify at a House Financial Services Committee hearing on...

Renzo’s ezETH depegs to $688 following end of airdrop farming window

Despite the temporary price depeg, a trader made nearly $400,000 in profit due to the unfortunate incident. Original Source...

EU conducts ‘dawn raid’ on Chinese security equipment supplier

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects her favourite stories in this weekly...

How a tiny group of US lawmakers and aides wrote the TikTok ban bill, concealing their efforts to avoid TikTok's lobbying, alongside the DOJ...

New York Times: How a tiny group of US lawmakers and aides wrote the TikTok ban bill, concealing...

Donald Trump Has A Massive Pennsylvania Problem

The Pennsylvania presidential primary didn’t have any contested contests, but Trump managed to lose nearly 17% of the...

Must Read

Trump Runs Away When Asked If He Still Supports Mike Johnson

Maybe he was still groggy from napping all...

EU conducts ‘dawn raid’ on Chinese security equipment supplier

Unlock the Editor’s Digest for freeRoula Khalaf, Editor...
- Advertisement -

You might also likeRELATED
Recommended to you